Venous thromboembolism (VTE) is a common issue in patients with autoimmune diseases. One of the clinically relevant issues for VTE in autoimmune disorders is the optimal duration of anticoagulation therapy for the prevention of recurrent VTE. Currently, autoimmune disorders are thought to be a relatively strong risk factor for recurrent VTE, which leads to the recommendation of extended anticoagulation therapy of indefinite duration in the current VTE guidelines [1]. However, these considerations have been based on observational studies.
